|1.||Jones, Ronald N: 15 articles (04/2014 - 07/2005)|
|2.||Falagas, Matthew E: 13 articles (04/2015 - 08/2006)|
|3.||Rybak, Michael J: 11 articles (12/2015 - 08/2002)|
|4.||Peloquin, Charles A: 10 articles (04/2015 - 08/2003)|
|5.||Grau, Santiago: 9 articles (11/2015 - 08/2005)|
|6.||Tsuji, Yasuhiro: 9 articles (01/2015 - 04/2008)|
|7.||Huang, David B: 9 articles (10/2013 - 09/2010)|
|8.||Bruss, Jon B: 9 articles (09/2003 - 08/2002)|
|9.||Caillon, Jocelyne: 8 articles (05/2015 - 12/2002)|
|10.||Mendes, Rodrigo E: 8 articles (04/2014 - 06/2008)|
08/01/2001 - "The preclinical promise of linezolid was realized in human clinical trials where linezolid was highly efficacious in the treatment of medically significant Gram-positive infections."
06/01/2012 - "All cases exhibited long-term tolerance of linezolid, and 14 of 15 cases showed either an improvement in or complete clearance of the infection. "
08/27/2015 - "In MRSA systemic infection mice models, 10f phosphate exerted significantly improved survival protection compared with linezolid. "
08/01/2011 - "Linezolid, the first US Food & Drug Administration-approved oxazolidinone, offers a valuable novel treatment option for serious gram-positive infections. "
04/05/2003 - "Several arguments (frequent implication of Streptococcus pyogenes and Staphylococcus aureus, well-adapted spectrum, changing resistance pattern of Gram-positive cocci, efficacy against associated bacteriemia, favorable kinetics and diffusion data in cutaneous tissues) argue in favor of the use of linezolid in infections of the skin and soft tissues"
06/01/2011 - "After the change from VCM to linezolid (LZD), the VAP improved promptly, indicating that LZD is superior to VCM in the treatment of MRSA pneumonia."
09/01/2014 - "In summary, linezolid may be a cost-effective treatment strategy in MRSA-confirmed nosocomial pneumonia."
02/01/2001 - "Linezolid is a well-tolerated, effective treatment for adults with gram-positive nosocomial pneumonia."
05/01/2001 - "To determine the safety, tolerance, pharmacokinetics and efficacy of linezolid, a new oxazolidinone antibiotic in the treatment of community-acquired pneumonia in hospitalized children. "
12/01/2010 - "Data from 7 Phase II and III clinical trials that assessed the efficacy of linezolid in community- or hospital-acquired pneumonia were pooled. "
08/01/2003 - "We report a case of resistant Staphylococcus epidermidis endocarditis that failed to respond to conventional antibiotic therapy but was treated successfully with an oral regimen of a new antibiotic, linezolid as a single active agent. "
08/01/2008 - "Orally administered linezolid is effective in limiting bacterial growth in the secondary foci of endocarditis. "
08/01/2006 - "We carried out a review of the available literature to evaluate whether linezolid is also effective for the treatment of patients with infective endocarditis. "
02/15/2004 - "Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. "
02/01/2006 - "There are no experimental studies regarding the prophylactic efficacy of linezolid against infective endocarditis. "
|4.||Soft Tissue Infections
05/01/2009 - "Linezolid may be considered as a cost-effective treatment for patients with complicated skin and soft-tissue infections suspected to be MRSA related in France."
07/01/2015 - "Phase III clinical trials have demonstrated that TDZ 200 mg daily for 6 days is noninferior to linezolid 600 mg twice daily for 10 days in the treatment of adults with skin and soft tissue infections caused or suspected to be caused by gram-positive organisms. "
04/01/2003 - "A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid."
01/01/2003 - "Results from this randomized trial show that linezolid can significantly reduce LOS for patients with complicated skin and soft tissue infections from suspected or confirmed methicillin-resistant staphylococci."
09/01/2014 - "Target site pharmacokinetics of linezolid after single and multiple doses in diabetic patients with soft tissue infection."
05/01/2014 - "These findings suggest that dose adjustment of linezolid is effective in preventing thrombocytopenia without reducing its clinical efficacy in patients having risk factors. "
05/01/2014 - "The aim of the present study was to evaluate the efficacy of dose modification based on the risk factor for linezolid-induced thrombocytopenia. "
06/01/2015 - "The present study was to evaluate the incidence of thrombocytopenia in ACLF and non-ACLF patients treated with linezolid and the risk factors of thrombocytopenia in these patients. "
09/01/2014 - "Therefore, the aims of the present study were to define PD thresholds that would minimise linezolid-induced thrombocytopenia and to perform a population PK analysis to identify factors influencing the pharmacokinetics of linezolid. "
08/01/2014 - "The aim of this study is to evaluate the risk factors for thrombocytopenia in patients who undergo linezolid therapy. "
|2.||Anti-Bacterial Agents (Antibiotics)
|10.||Oxazolidinones (2 Oxazolidone)
|4.||Transplantation (Transplant Recipients)